{"id":"NCT00367835","sponsor":"Shire","briefTitle":"SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms","officialTitle":"A Double-Blind, Randomized, Multi-Center, Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 (Guanfacine Hydrochloride) in Children Aged 6-12 With Symptoms of Oppositionality and a Diagnosis of Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12-04","primaryCompletion":"2008-01-04","completion":"2008-01-04","firstPosted":"2006-08-23","resultsPosted":"2009-11-26","lastUpdate":"2021-06-14"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"SPD503 (Guanfacine hydrochloride)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SPD503 (Guanfacine hydrochloride)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.","primaryOutcome":{"measure":"Change From Baseline in the Oppositional Subscale of the Conners' Parent Rating Scale-Revised Long Form (CPRS-R:L) Score at Up to 8 Weeks","timeFrame":"Baseline and up to 8 weeks","effectByArm":[{"arm":"SPD503","deltaMin":-10.8,"sd":7.23},{"arm":"Placebo","deltaMin":-7,"sd":7.63}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":34,"countries":["United States"]},"refs":{"pmids":["20806988"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html","http://www.intuniv.com/documents/INTUNIV_Full_Prescribing_Information.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":136},"commonTop":["Somnolence","Headache","Sedation","Fatigue","Abdominal pain upper"]}}